EAG Laboratories Adds Capabilities in Dermal Absorption Testing

On Jan. 18, 2017, EAG Laboratories announced the addition of dermal absorption studies to its suite of good laboratory practice-compliant testing services. Dermal absorption studies help pharmaceutical manufacturers evaluate skin absorption of topical drug delivery systems and over-the-counter pharmaceutical products. EAG Laboratories now offers testing outlined in Organisation for Economic Co-operation and Development (OECD) 427 (in vivo studies in rodent models) and OECD 428 (in-vitro studies using human and animal skin), which are often performed in parallel to predict dermal absorption in humans (sometimes called “the triple pack” or “parallelogram” approach).

Bill Reifenrath, a leading expert in dermal absorption, has joined EAG Laboratories’ Hercules, California location as Senior Scientific Advisor. Having been involved in early research that helped establish test guidelines in the 1990s, Dr. Reifenrath is a pioneer in the development and refinement of dermal absorption techniques used to screen topical pharmaceuticals and evaluate dermal absorption of chemicals for risk assessments. 

EAG Laboratories performs dermal absorption studies with ¹⁴C radiolabeled or non-radiolabeled test substances in a variety of formulations including solids, dusts, solutions, suspensions, and vapor exposures. The company employs a variety of custom-made diffusion cells that can be used for dermal absorption studies with complex products, including trapping devices for mass balance recovery of volatile chemicals.